BACKGROUND: Circulating lymphocytes of obese individuals with and without type 2 diabetes have derangements of pyruvate dehydrogenase (PDH) that are described as re¯ecting a disorder underlying systemic insulin resistance, namely basal activity below normal and, in vitro, unresponsiveness to insulin at 33 pmolal and activation at 330 pmolal instead of activation and inhibition as in controls. OBJECTIVE: To explore whether the above enzyme derangements are overcome in obese individuals on dexfenuramine treatment, known to improve poor peripheral insulin sensitivity. 
Introduction
Obese individuals with and without type 2 diabetes have derangements of pyruvate dehydrogenase (PDH) [1.2.4 .1] in their circulating lymphocytes that re¯ect a disorder underlying systemic insulin resistance. 1 That is, in vivo PDH activity is below normal and, in vitro, it is unaffected by insulin at relatively low (33 pmolal) and enhanced at relatively high (330 pmolal) physiological concentrations. In controls, however, insulin succeeds in stimulating PDH at just 16 pmolal; peak enzyme activation is reached with insulin at 33 pmolal, but for insulin at 66 pmolal enzyme activity is again at basal values and signi®cantly below for insulin at 330 pmolal. 1 ± 4 In the above obese subjects PDH protein content is not defective. 1 PDH is the major determinant of glucose breakdown for energy purposes as well as of glucose utilization for fatty acid synthesis and it is well documented as a sensitive insulin target. 5 ± 10 Dexfenuramine is known to have bene®cial effects on poor insulin sensitivity concerning de®ned metabolic pathways. 11 ± 17 However, the mechanism underlying this effect is not clearly understood and is envisaged to involve components beyond the insulin receptor. 12 Here we explore whether in obese individuals with and without type 2 diabetes, dexfen¯uramine ameliorates the above-mentioned PDH derangements. In mammalian tissues PDH is present in mitochondria as a polymeric protein (PDH complex, PDC), in which one of the subunits exists in a balance between a phosphorylated inactive (PDHb) and a dephosphorylated active (PDHa) form, thereby playing the role of a regulatory component. The conversion of one form into the other is controlled by a speci®c kinase (PDH kinase) and a speci®c phosphatase (PDHP phosphatase). PDH activity can thus be expressed as the activity of the already active PDC (PDHa activity), and as PDC total activity (PDHt), which can be measured by determining experimentally the full conversion of PDHb into PDHa; PDHt thus represents the actual amount of PDH protein in a sample. Of note, in the control exerted by insulin over PDH, PDHP phosphatase is regarded as the actual insulin target.
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Methods
Subjects
The case series was made up by 30 age-matched obese individuals. Fifteen (nine males and six females) were affected by type 2 diabetes, diagnosed according to the recommendations of the National Diabetes Data Group (NDDG); 18 they had been ill for no longer than 2 y, and controlled their blood glucose by dieting. Fifteen (three males and 12 females) were euglycaemic in fasting conditions, had normal glucose tolerance, assessed by an oral glucose load (OGT test), and had been on an unrestricted diet for 3 months; in addition they were all free from a family history of type 2 diabetes for at least two generations. All participants of this trial were from a larger case series of a previous study, aimed at evaluating PDH activity in their circulating lymphocytes and its response to insulin in vitro. They were obtained by selecting from that case series those obese diabetic and non-diabetic individuals who were free from hypertension and a family history for this disorder. We adopted blood pressure values of 140a80 for obese non-diabetic, and 145a85 for obese diabetic participants as a cut-off. All participants were asked not to modify their physical activity and dietary habits during the study. Lastly, no individual had liver or kidney disorders, as assessed by standard laboratory examinations; none had received pharmacological treatment for their obesity, and none had taken, during the previous 3 months, drugs that could affect glucose tolerance status.
Clinical and haematological parameters are summarized in Table 1 
Clinical parameters
The OGT test was carried out according to the recommendations of the NDDG. 18 The areas under the glycaemic (G-AUC) and insulinaemic (I-AUC) curves were calculated according to the trapezoidal rule 19 for time intervals of 30 min over a time of 2 h. Fasting insulin resistance index (FIRI) was estimated according to Duncan et al, 20 who consider this parameter a measure of insulin sensitivity.
Plasma glucose concentrations were estimated by a glucoseahexokinaseaATP spectrophotometric method (Kit Glu, Roche, SYS3 BM Hitachi 747a737). Serum insulin was evaluated in duplicate by immunoradio- Dexfen¯uramine and insulin resistance M Piccinini et al metric assay from Sorin Biomedica, Saluggia, Italy. The assay sensitivity was 4 AE 0.3 mUaml. The interand intra-assay variation coef®cients were 5.9 ± 6.3% and 3.5 ± 7.8%, respectively.
Lymphocyte preparation
Blood samples were collected in disposable vials containing 10% EDTA pH 7.4 (1 mla10 ml blood) and diluted 1:1 with 156 mm NaCl. Circulating lymphocyte preparation was performed according to Boyu Èm as previously reported. 1, 3 At the end of preparation, cells were suspended in 110 mm NaCl buffered in 40 mm Na 2 HPO 4 ± KH 2 PO 4 pH 7.4 (PBS-A). One part of the preparation was used immediately for insulin contact procedures, another part for cell counts, performed manually with a haemocytometer, and the remainder was pelleted, suspended in PBS-A enriched with 2 mgaml leupeptin and 20 mM EDTA (PBS-B), stored at 770 C and eventually used to evaluate PDH activity.
Cell incubation
Exposure of circulating lymphocytes to insulin was performed with intact fresh cells from blood samples taken at D -21 , D 0 and D 21 . Cells were suspended in PBS-A (2 ± 3Â10 6 cellsaml) and incubated in a ®nal volume of 200 ml with insulin at 33 or 330 pmolal in a medium containing 10 mm phosphate buffer pH 7.4, 0.1 mgaml bovine serum albumin (BSA), 50 mM CaCl 2 and 50 mM MgCl 2 .
1 After 15 min at 37 C they were supplemented with 1 ml PBS-A, centrifuged, washed twice with PBS-A, suspended in PBS-B, frozen at 770 C and eventually used in the PDH activity assay. Control samples were run in parallel without insulin.
Cell viability, at the end of the incubation, was close to 98%, assessed by Trypan blue exclusion.
PDH activity assay
PDH activity was evaluated on isolated cells at D -21 , D 0 , D 2 and D 21 , disrupted by cryolysis followed by sonication at 4 C. Lysed cells were incubated, in a ®nal volume of 100 ml, with 0.2 mgaml BSA, 10 mm Tris ± HCl pH 8, 1 mm dithiothreitol (DTT) and (a) 50 mm NaF, 1 mm dichloroacetate, 1 to test the amount of PDHa expressed as PDHa activity, or (b) 50 mM CaCl 2 and 10 mm MgCl 2 and excess of exogenous PDHP phosphatase to test, as previously reported, 1 the total amount of PDH expressed as total PDH activity (PDHt). After 10 min at 37 C, samples were supplemented with the assay reagents: 1 mm CoA, 1 mm NAD , 20 mm cysteine, 20 mm pyruvate, 80 mm phosphate buffer pH 8, 0.1 U lactic dehydrogenase and excess of phosphotransacetylase in a ®nal volume of 250 ml; samples preincubated with NaF were also enriched with 1.2 mm MgCl 2 . The reaction was stopped with 45 mm HClO 4 after 30 min at 37 C.
Deproteinized samples were neutralized at pH 7.4 and tested for the acetyl phosphate formed. 1 
Statistical analysis
The normal distribution of continuous variables was checked using the Kolmogorov Smirnow test. 21 In the repeated measure design (PDHa activity, FIRI, G-AUC and I-AUC), analysis of variance was performed and post-hoc comparisons were made according to the Newman ± Keuls test. Student's t-test for dependent samples was used for comparisons between means of fasting glycaemia (FG), fasting insulinaemia (FI), and FIRI at D 0 and D 21 . 22 The
Results
In all participants, clinical and haematological parameters were stable during the run-in period (D -21 ± D 0 ); basal and insulin stimulated PDH activities in their circulating lymphocytes were also constant, as were the in vitro derangements, described in the Introduction. Hence, only data referred to D 0 were used for comparisons.
At D 21 , in the diabetic group, weight decreased signi®cantly, as did FG, FI, FIRI and G-AUC, but not I-AUC (Table 1 and Figure 2) ; in the non-diabetic group, weight decreased signi®cantly, as did FI, FIRI, I-AUC and G-AUC, but not FG (Table 1 and Figure  3 ). Basal PDH activity in circulating lymphocytes of all participants recovered signi®cantly (P`0.0001), thereby approaching that of age-matched controls, 1 ( Figure 1 ± 3) ; further, in vitro, insulin at 33 pmolal, now determined sharp enzyme activation and at 330 pmolal clear inhibition (P`0.0001 and P`0.001 respectively, vs unstimulated cells; Figure  1) ; these responses were similar to those in controls. 1 At D 2 , when clinical and haematological parameters were still constant, basal PDH activity had already recovered signi®cantly with respect to D 0 (P`0.0001). However, with respect to D 21 , the difference was still signi®cant in the diabetic (P`0.001), but not in the non-diabetic group (P 0.06, Figures 2 and 3) 21 , and D 0 , respectively) and comparable to that in controls. 1 
Dexfen¯uramine and insulin resistance M Piccinini et al
Discussion
The PDH derangements, characterizing this case series at D -21 and D 0 , are no longer appreciable at D 21 . This improvement occurs along with amelioration of clinical parameters, in particular FIRI, which is considered a measure of peripheral insulin sensitivity. 20 However, already at D 2 PDH activity is well on its way to recovery in the absence of any modi®cation of the above parameters. Thus, rather than being the consequence of clinical improvements, revived PDH activity at D 21 should be an early and primary effect of drug treatment. This conclusion appears to be of interest because the PDH derangements are reported to re¯ect a disorder underlying insulin resistance. 1 PDH activity is well known to be under insulin control in a variety of cells, including circulating lymphocytes 1 ± 4,10,23 ± 28 This control is thought to be exerted through intermediates, whose generation involves plasma membrane components. 4 In the participants of this study enzyme response to insulin, in vitro, is impaired before but not at the end of treatment, suggesting this is so also for generation of the intermediates, ie the plasma membrane is the site of an impairment targeted by dexfen¯uramine. In line with this conclusion is that, in improving insulin sensitivity, dexfen¯uramine is believed to target components beyond the insulin receptor 12 and evidence exists that defective metabolic insulin control in obese non-diabetic and diabetic individuals stems from a postreceptor impairment. 29 ± 34 Poor PDH activity and the in vitro alterations are never observed as single defects, ie they always come together. Since normalization of enzyme response to insulin in vitro at D 21 is also accompanied by recovery of enzyme activity, the above-mentioned plasma membrane impairment, targeted by dexfen¯uramine, should underlie not only the in vitro alterations but poor enzyme activity as well; thus, the disorder targeted by the drug is the same disorder reported to underlie all the enzyme derangements and to re¯ect insulin resistance. 1 The possibility the PDH derangements ®nd their origin in defects of the PDH complex (PDC) itself should be excluded because PDHt is constant throughout the trial and, in addition, PDC is not quantitatively defective (see Results and Ref. 1) . Further, since the enzyme alterations can be corrected and PDC is not quantitatively defective, the possibility that PDH gene expression is altered should be ruled out. However, there are diseases, unrelated to obesity and type 2 diabetes, in which defective PDH activity is related to incorrect gene expression. 35 ± 39 The fact the two groups of participants have similar PDH derangements before treatment, although insulin resistance is likely to be worse in the diabetic group, suggests all the participants, whether diabetic or not, have the same plasma membrane disorder. In this view, severity of insulin resistance would be related to concurring variables unrelated to the plasma membrane disorder itself and differently expressed in the two groups of participants. On the contrary, the effectiveness of dexfen¯uramine on the disorder, evaluated in terms of recovery of PDH activity, would be affected by these variables; in fact, at D 2 there are clear differences between the two groups in the rate of recovery of PDH activity, although in both cases the disorder is obviously an early drug target (in the non-diabetic participants at D 2 PDH activity is PDH activity refers to the complex already in the active form (PDHa); in circulating lymphocytes from healthy controls not exposed or exposed to insulin at 33 and 330 pmolal the levels were 25.9 AE 1.7, 34.2 AE 2.9, and 20.2 AE 2.3 nmola10 6 cellsah, respectively. Dexfen¯uramine and insulin resistance M Piccinini et al no longer signi®cantly below that at D 21 but is still so in the diabetic ones, although in both groups it is signi®cantly above the value at D 0 ). The above PDH derangements re¯ect similar derangements in some other tissues. In obese diabetic patients PDH activity is below normal in skeletal muscle, 40 and evidence suggests this is so also in obese non-diabetic individuals; 41 instead, in adipocytes of obese diabetic and non-diabetic subjects it is normal, although in vitro in these cells the enzyme response to insulin is abnormal. 42 As mentioned, PDH accomplishes a dual metabolic role in that it shifts glucose intermediates from anaerobic glycolysis either towards complete oxidation in the Krebs cycle, with ensuing energy production (skeletal muscle, brain and heart), or towards conversion into precursors for fatty acid synthesis and ensuing fat mass deposition (adipose tissue, mammary gland and liver). 43, 44 In obese subjects fat mass deposition may thus constitute a protection against potential hyperglycaemia in the case where glucose consumption for energy purposes is compromised. Of note is that insulin is also a lipogenic factor and thus the relatively high blood insulin concentration obese subjects usually have promotes glucose consumption for fat mass deposition. However, if the necessary high blood insulin concentration can no longer be satis®ed, glucose consumption for fat mass deposition should decrease, thus increasing the risk of hyperglycaemia. At D 21 FI actually does fall in both groups of participants, but there is a concomitant fall of g-AUC in the obese non-diabetic participants and of FG and g-AUC in the diabetic counterparts. The reduced lipogenic action of insulin (fall of FI) should explain weight loss at this time. However, the concomitant decrease of g-AUC and FG means that dexfen¯ura-mine treatment improves glucose utilization in those tissues involved in using glucose prevalently for energy requirements and this should be another reason for weight loss. Since circulating lymphocytes actively utilize glucose for energy purposes, they too should belong to the above category of tissues including skeletal muscle, heart and brain (although their contribution to blood glucose homeostasis is obviously minimal). In this context, recovery in these cells of PDH activity following dexfen¯uramine treatment supports the view that dexfen¯uramine treatment ameliorates glucose utilization through oxidative pathways, there where this route is impaired.
We conclude that improved insulin sensitivity and weight loss, in obese non-diabetic and obese diabetic individuals following dexfen¯uramine treatment, are preceded by correction of the disorder, which the PDH derangements in circulating lymphocytes re¯ect, and which is believed to underlie insulin resistance. 1 In addition this study shows that the disorder is reversible, a characteristic trait also of insulin resistance, and suggests ways in which the drug attains its clinical effects. Lastly, signi®cant recovery of PDH activity already at D 2 suggests that enzyme activity in circulating lymphocytes is an early marker of the success which drugs aimed at improving insulin resistance will have in clinical terms.
In a previous study 4 it was seen that low PDH activity and deranged enzyme response to insulin in vitro also characterize circulating lymphocytes of lean patients with type 2 diabetes; in that study it was also seen that, in these cells, following exposure to insulin and sulphonylurea agents, the in vitro derangements revert to normal, and in vivo following drug treatment, PDH activity recovers along with normalization of glycaemia. 4 In that study too, amelioration of PDH derangements was related to a correction of a plasma membrane defect. However, the safety of dexfen¯ur-amine treatment has recently been questioned. It might thus be worthwhile placing the serotoninergic effects of dexfen¯uramine, 45 not a feature of sulphonylureas, under closer scrutiny. Comparative evaluation of the differences between these drugs may help to develop molecules more potent in the treatment of insulin resistance and free from some of their unwanted characteristics.
